Clinical trials: Rivaroxaban
Venous Thromboembolism
REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.
Patients with unprovoked venous thromboembolism (VTE) or VTE associated with persistent risk factors have a high risk of recurrence after stopping anticoagulation.
- Trial name
- RENOVE (NCT03285438)
- Testing
- Reduced dose of DOAC, Full dose of DOAC
- Where
- 39 sites in France
- Volunteers
- 2,774 people
- Sponsor
- University Hospital, Brest
Atrial Fibrillation
Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care
This study will characterize patients with ischemic stroke, a condition which occurs when a vessel supplying blood to the brain is obstructed, and a subpopulation of patients with irregular and often rapid heart rate (atrial…
- Trial name
- BEST-AF (NCT04099238)
- Testing
- Oral anticoagulant
- Where
- United Kingdom
- Volunteers
- 3,739 people
- Sponsor
- Bayer
Atrial Fibrillation
Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study
In patients with atrial fibrillation (AF) complicated with coronary artery disease (CAD), antiplatelet drugs are commonly used for the prevention of recurrence of stent thrombosis and cardiovascular events in combination with…
- Trial name
- AFIRE (NCT02642419)
- Testing
- Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel), Rivaroxaban
- Where
- Japan
- Volunteers
- 2,200 people
- Sponsor
- Japan Cardiovascular Research Foundation
Prosthesis; Cardiac, Heart, Functional Disturbance as Result
Rivaroxaban in Mechanical Valves: RMV Study
Anticoagulant treatment reduces the incidence of death and cardioembolic events in patients with atrial fibrillation or prosthetic heart valve and the incidence of death and recurrences in patients with VTE.
- Trial name
- RMV (NCT02894307)
- Testing
- Rivaroxaban
- Sponsor
- Hospital Ana Nery
Atrial Fibrillation, Osteoarthritis of the Knee
Assays for and Reversal of New Anticoagulants
New anticoagulants are being introduced to replace warfarin. These drugs do not require monitoring and are safer. There is currently no recommended way to reverse these drugs rapidly in the event of undue bleeding or need for…
- Conditions
- Atrial Fibrillation, Osteoarthritis of the Knee, Osteoarthritis of the Hip
- Trial name
- NCT01795781
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- R.P.Herrmann
Cryptogenic Ischemic Stroke, Patent Foramen Ovale
PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years
To assess whether PFO closure plus antiplatelet therapy is superior to antiplatelet therapy alone and whether oral anticoagulant therapy is superior to antiplatelet therapy to prevent stroke recurrence in patients aged 60 to 80…
- Trial name
- CLOSE-2 (NCT05387954)
- Testing
- Transcatheter PFO closure, Oral Anticoagulant, Direct-Acting, Antiplatelet therapy
- Where
- 42 sites in France
- Volunteers
- 792 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Atrial Fibrillation
Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice
This population-based study will identify patients with rapid and irregular heartbeat which is not due to a fault with the heart valves (non-valvular atrial fibrillation) who initiate rivaroxaban, apixaban or warfarin as…
- Trial name
- SiERRA UK (NCT03847181)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban (Eliquis), Warfarin
- Where
- United Kingdom
- Volunteers
- 45,164 people
- Sponsor
- Bayer
Coronavirus Infection
Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial
Pragmatic randomized clinical trial of patients admitted to the hospital with confirmed COVID-19 infection and elevated D-Dimer.
- Trial name
- ACTION (NCT04394377)
- Testing
- Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed, Group 2: control group with enoxaparin 40mg/d
- Where
- 36 sites in Brazil
- Volunteers
- 615 people
- Sponsor
- Brazilian Clinical Research Institute
Non-valvular Atrial Fibrillation
Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program
This study is multicentric, single-blind, and interventional with a randomization into two parallel arm, between a standard of care information and an additional information of the patient, with a 12 month follow up.
- Trial name
- MONACO (NCT02422602)
- Testing
- Xarelto, Experimental: Personalized information intervention
- Where
- France
- Volunteers
- 196 people
- Sponsor
- University Hospital, Montpellier
Atrial Fibrillation
Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban
Evaluation of the performance of the 2MACE index in a population of nonvalvular atrial fibrillation (NVAF) patients treated with rivaroxaban in Spain
- Trial name
- EMIR (NCT02975453)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Spain
- Volunteers
- 1,481 people
- Sponsor
- Bayer
Healthy Subjects
Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese Volunteers
The study was designed as a single-site, randomized, open-label, four-period complete and replicate crossover. A single oral dose of 20 mg rivaroxaban tablet (test) and Xarelto®(reference) was given to the 72 healthy Chinese…
- Trial name
- NCT04424381
- Testing
- Rivaroxaban 20 MG Oral Tablet [Xarelto], Rivaroxaban 20 MG Oral Tablet
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Qingdao University
Atrial Fibrillation
Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In Colombia
The study aim to assess demographic and clinical characteristics , treatment patterns and as exploratory analysis will descriptively assess the time to clinical events of NVAF patients treated with oral anticoagulants (OACs) in…
- Trial name
- NCT04234698
- Where
- Colombia
- Volunteers
- 2,076 people
- Sponsor
- Pfizer
Deep Venous Thrombosis
Comparison Between Xarelto Versus Warfarin in the Recanalization Rate of Deep Venous Thrombosis in Patients Legs.
This is a prospective, randomized study, aiming to evaluate patients with Deep Venous Thrombosis in lower limbs and the recanalization rates evaluated with DUPLEX ultrasound, as so the clinical outcomes in patients submitted to…
- Trial name
- DVT (NCT02704598)
- Testing
- Rivaroxaban, Warfarin
- Where
- Brazil
- Volunteers
- 84 people
- Sponsor
- Hospital do Servidor Publico Estadual
Rivaroxaban, Thromboprophylaxis
Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports
Rivaroxaban has been developed in the various clinical settings.Although cancer-associated DVT or PE was included in previously programs, limited patients of the total populations were cancer patients with totally implantable…
- Conditions
- Rivaroxaban, Thromboprophylaxis, Cancer
- Trial name
- NCT04309240
- Testing
- Rivaroxaban
- Volunteers
- 204 people
- Sponsor
- LiuZhou People's Hospital
COVID -19
C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.
During the peak of the second COVID -19 wave, the hospitals were over-crowded. Many COVID -19 positive patients had to stay at home and reach out to their family physicians for guidance.
- Trial name
- NCT04935515
- Testing
- Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins, Oral low dose steroid, Intravenous Antibiotics with Low dose steroid.
- Where
- India
- Volunteers
- 25 people
- Sponsor
- Manimarane Arjunan, MD,DM (Cardiology)
Acute Ischemic Stroke, Transient Ischemic Attack
Rivaroxaban Acute Stroke Safety Study
Atrial fibrillation is a common cardiac arrhythmia and a major risk for ischemic stroke. Furthermore the risk of stroke is higher in the first month after transient ischemic attack (TIA)/stroke.
- Trial name
- RASS (NCT02279940)
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of Alberta
Ischemic Stroke
Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
The ARCHIMEDES study (Anti-inflammatory and anti-thRombotic therapy with colCHicine and low dose rIvaroxaban for Major adverse cardiovascular Events reDuction in ischEmic Stroke) will be a randomized, double-blind, 2x2 factorial…
- Trial name
- ARCHIMEDES (NCT06396858)
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet, Colchicine 0.5 MG
- Volunteers
- 4,500 people
- Sponsor
- Brazilian Clinical Research Institute
Atrial Fibrillation, Percutaneous Coronary Intervention
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
The primary purpose of this study is to evaluate the safety for 2 different rivaroxaban treatment strategies and one Vitamin K Antagonist (VKA) treatment strategy utilizing various combinations of dual antiplatelet therapy (DAPT)…
- Trial name
- PIONEER AF-PCI (NCT01830543)
- Testing
- rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg
- Where
- 348 sites in United States, Argentina and 23 more
- Volunteers
- 2,124 people
- Sponsor
- Janssen Scientific Affairs, LLC
Anticoagulation
Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy
To quantify rates of bleeding events and investigate the characteristics of prescribed patients, rates of bleeding events, persistence and healthcare resource utilization of Oral Anticoagulants (OACs) prescribed in routine…
- Trial name
- RE-FIT (NCT02921126)
- Where
- Italy
- Volunteers
- 9,914 people
- Sponsor
- Bristol-Myers Squibb
Lymphoma, Leukemia
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological…
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Venous Thromboembolic Disease
- Trial name
- HEM-DOAC (NCT07270263)
- Testing
- Apixaban, Rivaroxaban, low molecular weight heparin (enoxaparin sodium)
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Gdansk